This site is intended for healthcare professionals
Venous Thromboembolism (VTE) Learning Zone
Declaration of sponsorship Pfizer and Bristol Myers Squibb

eLearning

Declaration of sponsorship Pfizer and Bristol Myers Squibb
Read time: 70 mins
Last updated:25th Feb 2022
Published:25th Feb 2022

Test your knowledge and understanding of the clinical risk factors for VTE in cancer with our interactive eLearning Modules.

  • In Module 1, you will dive into the pathophysiology of VTE, its prevalence and incidence, and which cancers can pose the highest risk of thrombotic events to your patients
  • In Module 2, you will discover how risk of VTE is assessed in patients with cancer, what stratification tools exist, and current treatment options available

Course overview

On completion of this module participants should have a good understanding of:

  • why patients with cancer are at higher risk of venous thromboembolism (VTE) compared to the general population
  • which cancer types are associated with the highest risk of VTE and how individual risk can be assessed
  • how the prevalence and incidence of VTE in patients with cancer compares to the general population
  • the importance of cancer screening patients with unprovoked VTE

Evaluation questions will be asked at the end of the module. These are designed to test your knowledge and consolidate your learning.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Course overview

On completion of this module participants should have a good understanding of:

  • factors that increase risk of VTE in patients with cancer
  • the importance of determining whether the risk-benefit ratio favours thromboprophylaxis
  • some of the most commonly-used VTE risk stratification tools used in patients with cancer
  • challenges involved in the prevention and treatment of VTE in patients with cancer
  • the potential benefits of direct oral anticoagulants in this patient group

Evaluation questions will be asked at the end of the module. These are designed to test your knowledge and consolidate your learning.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: